222 related articles for article (PubMed ID: 11468187)
1. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Gao J; Richardson DR
Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
[TBL] [Abstract][Full Text] [Related]
2. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
3. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
4. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
5. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Richardson DR; Tran EH; Ponka P
Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
[TBL] [Abstract][Full Text] [Related]
6. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Le NT; Richardson DR
Carcinogenesis; 2003 Jun; 24(6):1045-58. PubMed ID: 12807743
[TBL] [Abstract][Full Text] [Related]
7. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
8. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
Richardson DR
Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
[TBL] [Abstract][Full Text] [Related]
9. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Richardson DR; Ponka P
J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
[TBL] [Abstract][Full Text] [Related]
10. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
Bláha K; Cikrt M; Nerudová J; Ponka HF
Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
12. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes.
Buss JL; Arduini E; Ponka P
Biochem Pharmacol; 2002 Dec; 64(12):1689-701. PubMed ID: 12445858
[TBL] [Abstract][Full Text] [Related]
13. Pyridoxal isonicotinoyl hydrazone and its analogues.
Buss JL; Hermes-Lima M; Ponka P
Adv Exp Med Biol; 2002; 509():205-29. PubMed ID: 12572996
[No Abstract] [Full Text] [Related]
14. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity.
Richardson DR; Bernhardt PV
J Biol Inorg Chem; 1999 Jun; 4(3):266-73. PubMed ID: 10439071
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
[TBL] [Abstract][Full Text] [Related]
16. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities.
Richardson DR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2061-3. PubMed ID: 9303419
[TBL] [Abstract][Full Text] [Related]
18. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
Buss JL; Arduini E; Shephard KC; Ponka P
Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Baker E; Vitolo ML; Webb J
Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
[TBL] [Abstract][Full Text] [Related]
20. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.
Ponka P; Richardson DR; Edward JT; Chubb FL
Can J Physiol Pharmacol; 1994 Jun; 72(6):659-66. PubMed ID: 7954097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]